During the placebo-controlled periods ( Phase 2 , PHOENIX 1 , PHOENIX 2 ) , rates of adverse events ( AEs ) were comparable among patients treated with placebo ( 50.4 % ) , with ustekinumab 45 mg ( 57.6 % ) , or with ustekinumab 90 mg ( 51.6 % ) ; similar findings were observed during the controlled period of the ACCEPT trial ( etanercept : 70.0 % ; ustekinumab 45 mg : 66.0 % ; and ustekinumab 90 mg : 69.2 % ) .
